New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...
By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...
For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...
News Medical on MSN6d
Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individualsFor overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback